Drug Shortages - June 2015
RheumNow is committed to reporting safety issues in our monthly Drug Safety Bulletins. Each month we will update you with reports of new, ongoing and resolved Drug Shortages that will affect the practicing rheumatologist.
RheumNow is committed to reporting safety issues in our monthly Drug Safety Bulletins. Each month we will update you with reports of new, ongoing and resolved Drug Shortages that will affect the practicing rheumatologist.
An Israeli crossover trial analyzed the efficacy of hyperbaric oxygen therapy (HBOT) in 60 patients with fibromyalgia.
A large ACP survey of over 18,000 US internal medicine residents shows they often incorporate cost of care in discussions and decisions, but may not know the data (citation source http://buff.ly/1KeLq0D).
A survey of internists and family practitioners shows that half of physicians are unaware of how opioids are abused.
Using Medicaid data from 2000-2006, 9,600 hydroxychloroquine new users were compared to 3,829 new users of immunosuppressive agents (IS) in patients with SLE. They assessed adherence using the MPR - the medication possession ratio.
Rheumatoid management hinges on choosing your best therapies first.
A 36 year-old white male butcher has right knee pain for 3 weeks. He noted a similar episode 5 years earlier and admits to a traumatic fall on that knee years ago. He denies fever, redness, warmth, other joints or other past medical problems. He only takes OTC ibuprofen prn.
Biosimilars are copies of the biologic medicines used to treat inflammatory and immunologic conditions such as rheumatoid arthritis, multiple sclerosis and cancer- potentially at lower costs.
A retrospective review of 1285 US male veterans showed the prevalence of inflammatory eye disease to be 2%. Uveitis was most common (most being anterior uveitis), followed by keratitis, scleritis, episcleritis, and acute ischemic optic neuropathy.
1998 marked the introduction of citrulline as a unique target in the pathogenesis of rheumatoid arthritis. The hallmark article by Schellekens et al in the Journal of Clinical Investigation has since been cited over 500 times. Dr.
The National Institute for Heath and Care Excellence has turned down Otezla for coverage under the U.K. healthcare system for psoriatic arthritis.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.